Exploring Charles River Laboratories

Spektron Systems has actively engaged in developing synthesis and test plans on five representative molecules representing designs for an antipsychotic medication. Primarily for the purposes of estimating testing costs at a detailed level, our approach is to select key in vitro and in vivo/behavioral tests that we can or have modeled already in silico.  These will include tests for pharmacokinetics, a toxicity (e.g. hERG inhibition), and a behavioral efficacy test such as Locomotor Activity or Pre-Pulse Inhibition.  These are key to approaching a pre-IND conference with the Food and Drug Administration.